Thank and call. the KORU we'll Safe addressing joining Harbor you, of as all call. slides refer measures This of the you on is like ask thanks you I'd non-GAAP first and conference Systems. Devin, to for note today's to all call our Medical to today's
recent we including will third first two, you'll strengthened through financial we've things on significant results As two quarter on initiative. position we've several But, number proud the be tailwinds. the on we today's of listed see had Slide of are gone XXXX, call our in a discussing a rebranding foremost, X, One, encouraging our October. and to industry advances be and NASDAQ. And corporate for
is as new brand. it corporate koru, following So, represents by with evolving beginnings unfurling a incredibly X, focus values strides, of our at-home of The the and new life beginnings. the our a KORU that spiral-shaped inspired do everything the fern in at on Systems, patient-centric rebranding at Medical's KORU reflects patients The rebrand to will that core we're drive systems you the to if widely our providing new company KORU symbol Slide Medical great mission to focus. made we've recognized medical. heart is we excited and go culture, infusion
rebranding assembled our financial team Immunoglobulin and the patient you outcomes whereas we've casting can top want relationships that transparent, operational Teamwork, product year's stakeholders, National team eve the and there we very with committed to rebranding enhanced the industry. patient to in all in of priority. this attendees continuing patients, Integrity, and joined and Directors. efficacy, Las of with our the form our our and and light we we're First us long-term employees, our is the patient will our from Vegas, with trusting including on message Board response drive that Conference a we as strong our the development management respect announcement and are made experience; positive Society believe folks goals. embraced be positive by and the Board customers, of towards honored We was tell our partners investors. to a really lead industry management safety I to
Gauge and Sets the we're our or and Barbara some time, satisfaction. SuperXX Needle The new of A changes conference HIgH-Flo the completed this is respect news Specialty IgNS, evaluated from the in comfort infusion poster our support on Santa use Set leakage. patient no the to comfort did Needle study, Sets Sets. patient The Needle registered site infusion that make overall conducted with HIgH-Flo overall in and found Since including pain, satisfaction, areas tolerability, the of improved of standard available SuperXX decreased XX with topic the performance the SuperXX on website. study time, swelling, that recently HIgH-Flo company's we of of Pharmacy, against
as and the strategy we a patient development infusion significant experience. time product improve one, was overall validates be our to decrease reinforces may believe tool While SuperXX valuable this and a our position it small was the a study, it that
we'll posted. expect a We limited XXXX, everyone is of SuperXX, commence already clearance FDA launch to received and QX which in keep
for Now, on third the our quarter. performance to
QX a third which the net million, million $X.X XX% a net sales, quarterly Slide is record sales. in XX% third sales margins improvement XX.X% in consecutive to and a quarter quarter quarter the You'll expanded last that in nearly see increase $X.X quarter. gross from reached This we've XXXX. the reported We of of in net third profit reported is XXXX record on of gross year's X, XX.X%
increased $X.XX $XXX,XXX in net or compared $XXX,XXX with $XXX,XXX profitability a last $X.XX share, to nearly We the XX% incurring during adjusted year. reflecting our to rose XX.X% expenses GAAP to GAAP leverage EBITDA margin XX.X% quarter. million and income per the diluted from quarter, achieved statement. profitable third are EBITDA inherent litigation or year's We despite per diluted our in in share last on income of $X.X basis, Adjusted
results ended will in with a strong Karen remain We third you cash also detail in we in the through million greater quarter financial and equivalents shortly. debt-free. $X.X and cash walk the position,
product XXXX, in the On which September nine Slide basis, markets XXXX. XXth, our remain XXth, this Of our for XXXX, million. of XXXX. revenue all ended and sales the sales $XX.X believe expand further over is $XX.X plus primary net to as you'll focused geographic generating we September growth $X.X our organic profile, net net footprint. that will previously growth month at were $XX.X net industry months our consistent our We with end approximating We totaled for total growth in on a trailing elevate last XX through X, penetrate sales XXXX, and continue from plan. our years, announced XX% annual million XX% strategic XXXX million million, see On XX sales note,
of Medical's years of appointment than of John On announced year, the Slide in and the KORU our bringing May X, healthcare medical Board. Board in XX Fletcher this new John joined we September as of National Chairman of Chairman named was Directors, work his Spectranetics, Philips Director the XXXX the Association of in by for acquired experience Year company. Corporate device which billion. for by of XXXX for John was $X.X Royal the as more
to home industry on experience draw perspective, leadership infusion deep of a provider innovative we to products. benefited preferred from have grow member specialty and evolve we our Board, In vision, counsel. John's a help As to of role, Medical his and continue KORU new and expect informed as John's
fortunate Board. and assembled with objectives. the last have recently put that take very thank are also a any great industry, of want was Goldberger, KORU of operating experience team the Device ability time gives individuals, Board in over their Biomedical CEO confidence and Chairman to up long-term the of achieve me these succeeded this leadership Dan to in financial months ethic, against I caliber and John and appointed I to whom Company. to our drive We as along work Dan would Medical's a our XX
in wish we Dan his to valuable our new of continue member Board we well endeavor, have are as of Dan very fortunate a While certainly Directors.
Slide X CIDP, and $XXX disease PIDD largest state our sub-Q therapy, primary end-markets, market brings a the for of us aggregate million. in total US currently comprises two markets to two which approximately addressable
convert potentially consumable are the receiving using the means sets needle IG our just PIDD, Our Of Freedom Freedom of patients estimated XXX,XXX minimum to XX,XXX at XX,XXX that therapy are This tubing. is and receiving comprised XX,XXX market the just that figure sub-QIG syringe therapy Freedom addressable system. have could and drivers, with system. of people to
average therapy CIDP IG are frequent be recurring products. annually. requires patient to of estimate is therapy lifelong are potentially more KORU patients that PIDD, because and we patient for of revenue system so conditions, because could chronic of Freedom These important using patients $XXX our higher Revenue generates per compared about the This as point users each Medical to doses Hizentra. CIDP an
and IG CIDP. and for devices the in PIDD leader are market delivery infusion We supply
of to of continued industry actually Beyond initiatives, that, in durability I'm these integrated and the stating use education infusion that our physician of helping and ease our conjunction confident efficacy, markets. the with Freedom system, growth is drive
see the US five current right a names portion the the of for our Hizentra of On you'll Sub-QIG significant of CSL market. the slide, approved by Behring represents side drugs business.
is to PIDD, in and the it's their products July, the Hizentra's method condition. launch. by is the plan aren't clearance Although launch with technically been our this We announced year it system working Freedom to for marketing. we've the preferred very approved Grifols plan the to the support by this drug latest featured closely Hizentra, Xembify treat of understand on Xembify for label Grifols prominently end of In system FDA and of and Grifols delivery the making
good significantly is should demand. IG continues news, condition expectation that will PADD, this positively impact We the therapy It as supply. view begin believe and it as be of diagnosed as increasing result to supply, efficacy and very patients awareness of this the of our which more and the treating validates elevates IG sub-Q lag a we
would prescribed not drugs sub-Q These our newly Freedom be other or diagnosed a patients, do and because cannibalize view, other replacement continue will the Hizentra that Hizentra be Xembify or should treatment undergoing believe with our we not for as be have sub-QIG to therapies, Importantly, system. to Xembify currently with patients used would delivered primarily drugs. in infusion
companies, Slide as This have immune successfully including are those therapies well our available continued opportunities treating IG growth focus pharma shift. identified and nature our of market reflects drugs market. we manufacturing from and on disorders the are X; developing which driving slide, industry, They with. expanding is conditions, as is this neurological post as a total the IG growth among of with and on have our significant new positioned industry well the competitive Xembify and to is presented we interest the growing, others. of are are disorders, Major a this vested manufactures Grifols, IG the opportunity support preclinical indicative approval. to their efforts applications. in blood
Grifols Prior in continue therapy, basis, drugs towards that focused that XX marks On sub-Q there are future. to the foreseeable for shift industry Xembify We the an their approval with a US believe therapy. developing approval will clearance. of on the IVIG IVIG Xembify the a of as strategy sub-Q was
and patients is sub-Q by However, preferred more frequently more prescribed. generally
net significantly. continue to growth QX and continues that to large teams with involving delivery in and In execute. Clinical component our XXXX, the system for the of are our method space. pharma plan, key trial Our as trial of affairs be are increased which drugs, Freedom sales medical we sub-Q companies using clinical strategic associated trials indications molecule clinical developing on a the innovation collaborate to with continuing
home the benefits a plan. The for slides believe that that troublesome you compared of macro the significant access, pressure, therapy, for travel a their some blood caregiver difficulty next on sense other need at low will office not the or of highlight support our home patients to sub-QIG of for require infuse veins poor or IVIG can infusion. a be required summarizes eliminates with few medical frail. as as provides ability the very are those to young autonomy, at center, chart strategic Sub-QIG which venous the see tenants we with doctor's therapy. venous as access, or their to of Beginning tailwinds growth and XX, such The to Slide
IVIG the feeling much healthy and These produce on This be therapeutic of absorption a to a schedules as are patients companies on in higher development for can the sub-QIG associated eliminated so constant on and the body consistent weekly, own sub-QIG and is day-to-day the This do four longer weeks. peaks stays chart self-infuse to period. level because during patients. troughs This for their with a even the with level every commercialization gradual and motive three activities. is more a their therapies. drug sustained illustrated and at the drug Sub-QIG sub-QIG, must phenomenon while companies revenue-per-patient Pharmaceutical of pursue compelling is administered for to provides model administered IVIG continue right. benefit can
be total accounting cost from study patients and Moving found $XX,XXX. after years pneumonia, a US primary than in medical patient study XX% XXXX to in is of the XX payer these declined The plans. and nearly used, The By cost in cost XXXX more five mean years. undiagnosed nearly had and very Slide this the patients XX% Even immunodeficiency at tailwind per the XX% XX% Foundation XX XX increase the for reimbursement. sinusitis, pharmaceutical to Jeffrey for $XX,XXX patients in for annual identified report patients positive PI for bronchitis comparison, believe from for therapy, post-diagnosis Modell XX; least diagnosis. containing a savings our IG diagnosis. IMS otitis, claims estimates database receiving after the We health treatment before million study with with the
and in average drug addition, X% in In XX% outpatient increase utilization. was a hospitalizations, there outpatient in annual visits, XX%
to cost with the XXXX XXXX, over medical not between CIDP, the of reinforces study, use phrases, depicted life and One and than highlight care. use patient IG $X.X IG CIDP value-based one PADD was patients also estimated of XX,XXX had longer Each The of prescribed $XX,XXX cost Modell such at billion. of studies XX% primary very our study controls. the of of an professionally therapy stay decline, the average lengths conditions in other which costs the for referenced other the definition healthcare of used. of and is operating and and here, improved. article Although is CIDP and monitored, CIDP quality hospitalizations the fall, of which for hospitalization analyzed when Modell assets and records Cost treat
healthcare trillion and a estimated IG XXX,XXX by XX, in States market today. This Services. opportunity. of is $X the remain patient immunodeficiencies large to component PADD Remember, under-diagnosed. the represents Primary the significantly population the for according reach are receiving market significant Slide XX% just spending expected therapy United the a in Centers XXXX, to spend. Medicaid Medicare are Specialty Pharmaceuticals of On
since has XX%. in administered per spending capita specialty on fact, annual averaged XXXX growth drugs In
per savings result per Based at Group, the per drugs The of can study, estimate Healthcare we by the United that $XX,XXX was $XX,XXX be in home, conducted year. found opposed as annual this over which Immune data, Deficiency hospital, can infusing period. patient, months savings per to six patient, on
them side physical patients' improve adverse can home effects. and work and reduce at to treatment family their responsibilities mental addition, and manage In well-being, allowed
the towards as component believe value-based an report discuss we move care. of important at-home the slide, we infusion the As validates last
much XX. with Moving industry on growth ours different. Slide to competition growth recorded no Any potential has and and is as
system using aspect Freedom While most there product many The of FDA the commonly types to the model, pumps recurring used pumps therapy. of and by allows sub-QIG mechanical which helps are cleared for the us is infusion the the system are market, revenue. the drive operate on razor-razorblade
immediately down a by mechanical Equilibrium, XX.X consistent slowing infusion. pressure of to Our the and throughout infusion maintaining Dynamic utilizes constant increase in response system which PSI or pressure
constant pumping increase to pumps possible pressure programmed This to lead site their tissue in rate. as within potential By cause pressures saturation flow, pumps, flow such increasing which electronic and drug. way discomfort, comparison, high infusion maintain by respond the of leakage for can designed of side, reactions, can
the products, is For easy system to compared steps. three patient, just our competing easy when use, very to
our point setting, Most waste importantly, drugs. we therapy. products train home sub-QIG to of important a and to drug cost high growing Freedom is to it's the it's patients when positioned of to support very the the the well considering minimum, is infusion highly kept believe For these easy very system the use accurate provider, in the adoption an
over turning specific becoming the roadmap preferred to our markets. for delivery Before in Karen, Slide see things to partner infusion you'll select on XX, therapies
baseline this clinical for pursuing approach with see, collaboration the KORU on growing can multifaceted usage. products, launching the these multi-year, new on in and with penetrating and business, you As developing to we team further our and involves execute we're at entire Right pharma objectives PADD now, focus trial companies and CIDP, Phase Medical. I are plan
to enter market strategy indications, a expansion geographies. we and continue and the year the focused products, I As commence our on will Phase plan of our XXXX, we execute innovation and
million to generating We our continue rate our our business year-end improving manage by revenue drive year-over-year. XXXX, organic and towards XX% the towards XX% a $XX to goal of the efficiencies goal growth margin run operating us
now a I'll the to discussion quarter. of Karen? over Karen for things turn
